IP
FBRX icon

Isthmus Partners’s Forte Biosciences FBRX Stock Holding History

Isthmus Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed -$1K – 188
2021
Q2 		$1K Buy
+1
New +$901 ﹤0.01% 260
2018
Q4 		– Sell
-1
Closed -$8K – 185
2018
Q3 		$8K Hold
1
– – ﹤0.01% 248
2018
Q2 		$5K Hold
1
– – ﹤0.01% 250
2018
Q1 		$6K Hold
1
– – ﹤0.01% 242
2017
Q4 		$5K Hold
1
– – ﹤0.01% 268
2017
Q3 		$6K Hold
1
– – ﹤0.01% 262
2017
Q2 		$6K Buy
+1
New +$5.63K ﹤0.01% 266

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Isthmus Partners's FBRX Position: Q3 2021 in Review

Isthmus Partners sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 1 share — an estimated $1K sold.

Isthmus Partners first reported a position in FBRX in Q2 2017 and held it in 7 quarters. The position peaked at $8K in Q3 2018. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Isthmus Partners reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Isthmus Partners sold 1 Forte Biosciences share in Q3 2021, an estimated $1K.
  • Isthmus Partners first reported a position in Forte Biosciences in Q2 2017 and held it in 7 quarters.
  • Isthmus Partners's Forte Biosciences position peaked at $8K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Isthmus Partners's 13F filing for Q3 2021, filed 10 Nov 2021.